Fairview Capital Investment Management’s AbbVie ABBV Stock Holding History

Fairview Capital Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19M	Buy	4,712 +142	+3%	+$30.6K	0.06%	102
2026 Q1	$994K	Sell	4,570 -36	-0.8%	-$7.99K	0.05%	105
2025 Q4	$1.05M	Sell	4,606 -89	-2%	-$20.3K	0.05%	97
2025 Q3	$1.09M	Buy	4,695 +215	+5%	+$43.8K	0.06%	98
2025 Q2	$832K	Sell	4,480 -54	-1%	-$10K	0.04%	99
2025 Q1	$950K	Sell	4,534 -194	-4%	-$37.7K	0.05%	91
2024 Q4	$840K	Sell	4,728 -460	-9%	-$84.6K	0.04%	94
2024 Q3	$1.02M	Buy	5,188 +1,000	+24%	+$187K	0.06%	88
2024 Q2	$718K	Sell	4,188 -8,800	-68%	-$1.46M	0.04%	97
2024 Q1	$2.37M	Buy	12,988 +158	+1%	+$27.2K	0.13%	73
2023 Q4	$1.99M	Buy	12,830 +165	+1%	+$24.1K	0.12%	72
2023 Q3	$1.89M	Hold	12,665	–	–	0.12%	71
2023 Q2	$1.71M	Sell	12,665 -250	-2%	-$36.7K	0.11%	74
2023 Q1	$2.06M	Buy	12,915 +597	+5%	+$91.3K	0.13%	70
2022 Q4	$1.99M	Sell	12,318 -98	-0.8%	-$15K	0.14%	69
2022 Q3	$1.67M	Hold	12,416	–	–	0.12%	68
2022 Q2	$1.9M	Buy	12,416 +8,800	+243%	+$1.34M	0.13%	67
2022 Q1	$586K	Buy	3,616 +283	+8%	+$41.1K	0.04%	93
2021 Q4	$451K	Sell	3,333 -54	-2%	-$6.38K	0.03%	99
2021 Q3	$365K	Buy	3,387 +54	+2%	+$6.17K	0.02%	102
2021 Q2	$375K	Hold	3,333	–	–	0.03%	100
2021 Q1	$360K	Hold	3,333	–	–	0.01%	135
2020 Q4	$357K	Hold	3,333	–	–	0.01%	120
2020 Q3	$291K	Hold	3,333	–	–	0.01%	115
2020 Q2	$327K	Hold	3,333	–	–	0.02%	106
2020 Q1	$253K	Hold	3,333	–	–	0.02%	119
2019 Q4	$295K	Sell	3,333 -225	-6%	-$18.7K	0.01%	123
2019 Q3	$269K	Hold	3,558	–	–	0.01%	129
2019 Q2	$258K	Hold	3,558	–	–	0.01%	132
2019 Q1	$286K	Hold	3,558	–	–	0.02%	123
2018 Q4	$328K	Hold	3,558	–	–	0.02%	120
2018 Q3	$337K	Buy	3,558 +225	+7%	+$21.3K	0.02%	116
2018 Q2	$309K	Hold	3,333	–	–	0.02%	109
2018 Q1	$315K	Sell	3,333 -228	-6%	-$25K	0.02%	102
2017 Q4	$344K	Hold	3,561	–	–	0.02%	94
2017 Q3	$316K	Hold	3,561	–	–	0.02%	95
2017 Q2	$258K	Hold	3,561	–	–	0.02%	98
2017 Q1	$232K	Hold	3,561	–	–	0.02%	88
2016 Q4	$223K	Hold	3,561	–	–	0.02%	84
2016 Q3	$225K	Hold	3,561	–	–	0.02%	77
2016 Q2	$220K	Hold	3,561	–	–	0.02%	70
2016 Q1	$203K	Sell	3,561 -1,926	-35%	-$107K	0.02%	77
2015 Q4	$325K	Buy	5,487 +1,466	+36%	+$84.4K	0.03%	65
2015 Q3	$219K	Sell	4,021 -1,640	-29%	-$107K	0.02%	66
2015 Q2	$380K	Buy	5,661 +928	+20%	+$60.6K	0.03%	60
2015 Q1	$277K	Hold	4,733	–	–	0.02%	64
2014 Q4	$310K	Sell	4,733 -300	-6%	-$18.9K	0.02%	69
2014 Q3	$291K	Sell	5,033 -400	-7%	-$22.2K	0.02%	67
2014 Q2	$307K	Hold	5,433	–	–	0.03%	68
2014 Q1	$279K	Hold	5,433	–	–	0.02%	66
2013 Q4	$287K	Sell	5,433 -300	-5%	-$14.7K	0.03%	64
2013 Q3	$256K	Hold	5,733	–	–	0.02%	62
2013 Q2	$237K	Buy	+5,733	New	+$251K	0.02%	65

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fairview Capital Investment Management's ABBV Position: Q2 2026 in Review

Fairview Capital Investment Management increased its AbbVie (ABBV) stake by 3.1% in Q2 2026, buying an estimated $30.6K and bringing the position to 4,712 shares worth $1.19M. The position accounts for 0.06% of the portfolio, ranked #102.

Fairview Capital Investment Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.37M in Q1 2024. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Fairview Capital Investment Management held 4,712 shares of AbbVie worth $1.19M as of Q2 2026.
Fairview Capital Investment Management bought 142 AbbVie shares in Q2 2026, an estimated $30.6K.
AbbVie made up 0.06% of Fairview Capital Investment Management's portfolio in Q2 2026, its #102 holding.
Fairview Capital Investment Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
Fairview Capital Investment Management's AbbVie position peaked at $2.37M in Q1 2024.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Fairview Capital Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.